logo
Plus   Neg
Share
Email

United Therapeutics Signs Deal With DEKA For New Remodulin Delivery System

United Therapeutics Corp. (UTHR) said it has signed an agreement with DEKA Research & Development Corp. for the development of a potential technology breakthrough in the subcutaneous delivery of Remodulin or treprostinil Injection to patients with pulmonary arterial hypertension via a pre-filled semi-disposable pump system. Financial terms of the agreement were not announced.

United Therapeutics expects to introduce the new subcutaneous Remodulin delivery system in the 2016-2018 timeframe.

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension or PAH to diminish symptoms associated with exercise.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amazon.com Inc. will continue to work with the U.S. Department of Defense or DoD despite criticism from its employees and privacy activists, the company's Founder and Chief Executive Jeff Bezos said Monday. "If big tech companies are going to turn their back on the DoD, this country is going to be in trouble," Bezos said during the Wired25 conference in San Francisco. The Goldman Sachs Group, Inc. (GS) reported earnings per common share of $6.28 for the third quarter of 2018 compared to $5.02 for the third quarter of 2017. On average, 22 analysts polled by Thomson Reuters expected the company to report profit per share of $5.38 for the quarter. Analysts' estimates... Johnson & Johnson (JNJ) on Tuesday, while reporting financial results for the third quarter, raised its adjusted earnings and sales forecast for fiscal 2018. The company raised full-year outlook for adjusted earnings to a range of $8.13 to $8.18 per share. This reflects an increase in expected operational...
Follow RTT